GlassScriptPhysician profile
Steven D Edwards
NPI 1427246636
$1,572.88
in general payments reported to CMS, 2019-2025
23 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $119 · 2023: $295 · 2024: $493 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $242.91 | 2023-2025 | |
| Lilly USA, LLC | $164.04 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $131.89 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $124.38 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $120.28 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $107.61 | 2023-2025 | Veozah |
| Abbott Laboratories | $79.07 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $78.00 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $74.46 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $61.68 | 2024-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $54.40 | 2025 | |
| Idorsia Pharmaceuticals US INC | $51.34 | 2023-2024 | Quviviq |
| Organon LLC | $51.05 | 2024-2025 | Nexplanon |
| Axsome Therapeutics, INC. | $49.07 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.58 | 2024-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $36.46 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $21.27 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.36 | 2024 | |
| Dynavax Technologies Corporation | $15.31 | 2025 | Heplisav-B |
| Medtronic, INC. | $14.43 | 2022 | |
| Amgen INC. | $13.61 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $11.79 | 2021 | |
| Genentech USA, INC. | $8.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.